Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease

Blood

Volumn 110, Issue 2, 2007, Pages 776-782

  Kim, Juyang ^a   Kim, Hye J ^a   Park, Keunhee ^a   Kim, Jiyoung ^a   Choi, Hye Jeong ^b   Yagita, Hideo ^c   Nam, Seok H ^d   Cho, Hong R ^b   Kwon, Byungsuk ^a  

^a University of Ulsan   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Ajou University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ALOPECIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GENERAL HEALTH QUESTIONNAIRE; GRAFT VERSUS HOST REACTION; IMMUNOTHERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN FIBROSIS; ULCER;

EID: 34547125361     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-043612     Document Type: Article

References (46)

1. Gilliam AC. Update on graft versus host disease. J Invest Dermatol. 2003;123:251-257.
2. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood. 2005;105:4200-4206.
3. Jaffee BD, Claman HN. Chronic graft-versus-host disease (GVHD) as a model for scleroderma, I: description of model systems. Cell Immunol. 1983;77:1-12.
4. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999;163:5693-5699.
5. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168:3088-3099.
6. Nonomura A, Kono N, Minato H, Nakanuma Y. Diffuse biliary tract involvement mimicking primary sclerosing cholangitis in an experimental model of chronic graft-versus-host disease in mice. Pathol Int. 1998;48:421-427.
7. + T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112:101-108.
8. + T cells that survive irradiation regulate chronic graft-versus-host disease. Blood. 2004;104:1565-1573.
9. Li J, Helm K, Howell CD. Contributions of donor CD4 and CD8 cells to liver injury during murine graft-versus-host disease. Transplantation. 1996;62:1621-1628.
10. Nonomura A, Kono N, Mizukami Y, Nakanuma Y. Histological changes of the liver in experimental graft-versus-host disease across minor histocompatibility barriers, VII: a light and electron microscopic study of the large bile duct. Liver. 1993;13:163-171.
11. Vierling JM, Ruderman WB, Jaffee BD, Fennell RH Jr, Claman HN. Hepatic lesions in murine chronic graft-versus-host disease to minor histocompatibility antigens: a reproducible model of nonsuppurative destructive cholangitis. Transplantation. 1989;48:717-718.
12. Hamilton BA. L3T4-positive T cells participate in the introduction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol. 1987;139:2511-2515.
13. Anderson BE, McNiff JM, Jain D, et al. Distinct roles for donor- an host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005;105:2227-2234.
14. Kaplan DH, Anderson BE, McNiff JM, et al. Target antigens determine graft-versus-host disease phenotype. J Immunol 2004;173:5467-5475.
15. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005;26:587-595.
16. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000;105:1289-1298.
17. Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol. 2007;127:281-292.
18. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med. 2006;203:2785-2791.
19. + T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006;107:2993-3001.
20. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186:47-55.
21. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol. 1999;162:5037-5040.
22. Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffman MK. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med. 1999;190:1535-1540.
23. + T cells. Trends Immunol. 2002;23:378-380.
24. Sun Y, Lin X, Chen HM, et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol. 2002;168:1457-1465.
25. Shao H, Fu Y, Liao T, et al. Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells. Invest Ophthalmol Vis Sci. 2005;46:596-603.
26. Seo SK, Choi JH, Kim YH, et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med. 2004;10:1088-1094.
27. Foell JL, Diez-Mendiondo BI, Diez DH, et al. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology. 2004;113:89-98.
28. Sun Y, Chen HM, Subudhi SK, et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med. 2002;8:1405-1413.
29. 1 mice. J Clin Invest. 2003;111:1505-1518.
30. + T cells. Blood. 2005;105:2206-2213.
31. Fukushima A, Yamaguchi T, Ishida T, et al. Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice. J Immunol. 2005;175:4897-4903.
32. Cho YS, Kwon B, Lee TH, et al. 4-1BB stimulation inhibits allergen-specific immunoglobulin E production and airway hyper-reactivity but partially suppresses bronchial eosinophilic inflammation in a mouse asthma model. Clin Exp Allergy. 2006;36:377-385.
33. Polte T, Foell J, Werner C, et al. CD137-mediated immunotherapy for allergic asthma. J Clin Invest. 2006;116:1025-1036.
34. Sun Y, Blink SE, Liu W, et al. Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation. J Immunol. 2006;177:814-821.
35. Kayagaki N, Yamaguchi N, Nagao F, et al. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci U S A. 1997;94:3914-3919.
36. Ju ST, Panka DJ, Cui H, et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995;373:444-448.
37. Brunner T, Mogil RT, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediate activation-induced apoptosis in T-cell hybridomas. Nature. 1995;373:441-444.
38. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JLM. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204-3213.
39. + T cell priming through in vivo ligation of glucocorticoid-induced TNF receptor. J Immunol. 2006;176:5223-5231.
40. + T lymphocytes in vivo. Blood. 2004;103:177-178.
41. + T cell responses. Nat Immunol. 2002;3:536-541.
42. Pauley JM, Langstein J, Krammer PH, Schwarz H. CD137-induced apoptosis in independent of CD95. Immunology. 1999;98:42-46.
43. Yu XZ, Albert MH, Martin PJ, Ansasetti C. CD28 ligation induces transplantation tolerance by IFN-γ-dependent depletion of T cells that recognize alloantigens. J Clin Invest. 2004;113:1624-1630.
44. + T cells in graft-versus-host disease. J Exp Med. 2004;200:149-157.
45. Noncentini G, Guinchi L, Ronchetti S, et al. A new member of the tumor necrosis factor nerve growth factor receptor family inhibits T cell receptor-induced aoptosis. Proc Natl Aca Sci U S A. 1997;94:6216-6221.
46. Kwon B, Youn BS, Kwon BS. Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes. Curr Opin Immunol. 1999;11:340-345.